Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus irinotecan in advanced gastric or GEJ adenocarcinoma
NCT03116555Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Apr 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by China Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03116555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116555.